GE HealthCare
NASDAQ: GEHC
Stock price
64.22 USD
(+7.03%) 5 years
Financial Performance
5Y price score: 9
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 7%
%
ㅤ
By default your notes are visible only to you.
58.7
52-week range
89.7
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
3 %
Dividend Yield TTM
0.2 %
Market cap $
$ 29,007
Price / Earnings TTM
18.6
Price / Book TTM
2.7
PEG TTM
3.8
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
(14.3) %
7.6 %
7 %
Free cash flow per share growth
(7,880.5) %
4.2 %
-
Earnings per share growth
17 %
3.2 %
-
Founded: 1,994
Employees: 53,000
Business Summary:
Q&A
Contribute
By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more
Latest Earnings Call Takeaways
2026 Q2 (Jul 29, 2026)
1) Strong Orders and Backlog Growth - Orders increased by 11% year-over-year, with a record backlog of $23.9 billion, up $2.6 billion YoY. - Book-to-bill ratio stood at 1.15x, indicating strong demand across all segments. - The growth was broad-based, with significant contributions from ultrasound, MR, CT, and patient monitoring.
2) Financial Performance Highlights - Revenue for Q2 2026 was $5.3 billion, reflecting 3.5% organic growth YoY. - Product revenues grew by 4.7%, while service revenues saw a 7.7% increase. - Adjusted EBIT was $750 million, with an adjusted EBIT margin of 14.2%, down 40 basis points YoY. - Adjusted EPS reached $1.13, up 6.6% YoY, benefiting from tariff refunds and a lower tax rate.
3) Challenges in Patient Care Solutions - Patient Care Solutions (PCS) experienced a revenue decline of 13.5%, attributed to operational fulfillment challenges and supply chain issues. - Despite these challenges, PCS saw strong orders growth in monitoring, indicating potential for recovery. - A strategic review of PCS is underway to explore options for maximizing long-term growth, including potential sale or restructuring.
4) Innovation and Product Pipeline - The company is focused on launching new AI-enabled products, with several innovations expected to drive growth in the second half of 2026 and beyond. - Photonova Spectra, a photon-counting CT platform, is anticipated to enhance market opportunities post CE marking. - The pharmaceutical diagnostics segment reported strong growth of 14.6%, driven by increased adoption of disease-specific tracers and the Flyrcado ramp.
5) Guidance and Outlook - GE Healthcare maintains its full-year guidance of 3% to 4% organic sales growth and adjusted EBIT margin expansion of 10 to 40 basis points. - Adjusted EPS guidance remains at $4.80 to $5.00, with expectations for low double-digit growth YoY. - The call did not provide specific updates on the ongoing CFO search or detailed impacts from potential generic competition in the contrast media market.
Bottom line: GE Healthcare demonstrated robust order growth and a solid financial performance in Q2 2026, despite challenges in the PCS segment. The company's focus on innovation and strategic initiatives positions it well for continued growth, making it a compelling investment for shareholders.
Annual Reports, Presentations And IR Contacts
Go to the websiteGE HealthCare — Financial Overview, Stock Price, Market Cap
GE HealthCare is a company. Founded in 1994. As of October 9, 2026, the company's market capitalization is $29007291103 with a current stock price of $64.22.